![Raffaele Colombo: ADC history.](https://oncodaily.com/pub/uploads/2023/10/59982A6B-9B3C-4DE0-932A-87FFD7D8C585-1280x1268.jpeg)
Photo taken from Raffaele Colombo/Twitter
Oct 2, 2023, 18:10
Raffaele Colombo: ADC history.
Quoting Raffaele Colombo, Principal Scientists at Zyme Works on X/Twitter:
“Maytansine was isolated in the early ‘70s and tested in several clinical trials until 1984. Two ADC payloads derived from it, DM1 and DM4. T-DM1 was approved in 2013 and Mirvetuximab in 2022. But not so easy: 23 other maytansinoid ADCs got discontinued in the past 22 years! Camptothecin and auristatin ADCs for another time. Part of the T-DM1 history, the Refuse To File (RTF) letter for the accelerated approval of T-DM1 in 2010.”
Source: Raffaele Colombo/Twitter.